Medeor Therapeutics
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
611 Gateway Blvd Ste 120, South San Fran...Phone Number
(650) 627-4531Website
www.medeortx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Medeor Therapeutics
Medeor Therapeutics is focused on redefining kidney transplantation through its pioneering cellular immunotherapy aimed at achieving long-lasting immune tolerance. The company has completed a Phase 3 clinical trial for HLA-matched living donor kidney-transplant recipients, demonstrating promising results that are currently under review for publication. Medeor aims to eliminate the need for lifelong immunosuppressant drugs, which can have detrimental side effects, thereby improving the quality of life for transplant patients. The company is seeking potential acquirers to assist in completing the BLA filing and to further its mission of enhancing organ survival and patient outcomes.Explore more
Medeor Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Medeor Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Medeor Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Medeor Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Medeor Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Medeor Therapeutics
Product Launch: Get notified when Medeor Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Check out if Medeor Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once Medeor Therapeutics has new funding data
Medeor Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Medeor Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Medeor Therapeutics
Compare insights from companies similar to Medeor Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Medeor Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Medeor Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Medeor Therapeutics.
Medeor Therapeutics financials insights
Gather financial insights about Medeor Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Series B
$57M
2020
Debt
$150K
Medeor Therapeutics Tech Stack
A closer look at the technologies used by Medeor Therapeutics
See more technologies
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Facilities Relocation / Expansion
Medeor Therapeutics is planning to move its offices in December 2022. The move will impact approximately 35 employees at their existing office located at 611 Gateway Blvd , South San Francisco , CA.
Left Company
Executive Move
New Hire
Executive Move
New Hire
Funding
Medeor Therapeutics News & Media
Medeor Therapeutics to Provide Interim Results of Phase 3 Mercury Study of MDR-101 Cell Therapy in Living Donor Kidney Transplants During Rapid Fire Oral Presentation at ATC Virtual Congress
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Medeor Therapeutics will present interim results of its Phase 3 study clinical trial for MDR-101 cell therapy at the American Transplant Congress.Medeor Therapeutics Completes Enrollment and Transplantation for Pivotal Trial of MDR-101 Cell Therapy to Establish Tolerance in HLA-Matched Living Donor Kidney Transplants
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Medeor Therapeutics completed enrollment and kidney transplantation of all patients in its Phase 3 prospective, multicenter, randomized trial.Medeor Therapeutics Appoints Dr. Daniel Brennan as Chief Medical Officer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Medeor Therapeutics announces the appointment of Daniel Brennan as Chief Medical Officer.Medeor Therapeutics Announces Data Presentation at the American Society of Nephrology Kidney Week 2020
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Medeor Therapeutics announces that interim results from the company’s MERCURY Phase 3 clinical trial will be presented at ASN Kidney Week 2020
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Medeor Therapeutics
Sign Up For FreeTo access detailed company insights
Medeor Therapeutics is focused on redefining kidney transplantation through its pioneering cellular immunotherapy aimed at achieving long-lasting immune tolerance. The company has completed a Phase 3 clinical trial for HLA-matched living donor kidney-transplant recipients, demonstrating promising results that are currently under review for publicat... Read More
